Valganciclovir for Brain Cancer

This trial tests a treatment for individuals with brain metastases from breast cancer, specifically when the cytomegalovirus (CMV) is active. The trial evaluates the effectiveness and safety of Valganciclovir, an antiviral medication, in improving brain function and quality of life for these patients. Participants must have breast cancer that has spread to the brain and show signs of active CMV infection. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group of people.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

Research shows that Valganciclovir is generally safe for people. Studies have found that patients with glioblastoma, a type of brain cancer, can tolerate it well. One study added Valganciclovir to the usual treatment for these patients and found it to be safe. Another study supported these results, showing no major safety issues when Valganciclovir was used as an additional treatment. These studies suggest that Valganciclovir is likely safe for patients, but monitoring for any possible side effects during treatment remains important.¹²³⁴⁵

Valganciclovir is unique because it targets the human cytomegalovirus (HCMV) in brain cancer patients, which is not a typical focus of existing treatments. While most standard treatments for brain cancer involve surgery, radiation, or chemotherapy targeting tumor cells directly, Valganciclovir works differently by addressing viral components that might be influencing cancer progression. Researchers are excited about this approach because it introduces a new mechanism of action, potentially offering a complementary route to improve outcomes for patients with brain cancer.

Research has shown that the drug valganciclovir, administered alongside standard-of-care treatment, may aid in treating certain brain cancers. In patients with glioblastoma, those who received valganciclovir with standard treatment lived longer on average—24.1 months compared to 13.3 months for those who did not receive it. Another study found that patients treated with valganciclovir had higher survival rates over two years. These findings suggest that valganciclovir might improve outcomes for patients with brain tumors linked to the reactivation of the cytomegalovirus (CMV).¹³⁶⁷⁸